Medical Microbiology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, Netherlands.
Department of Bionanoscience, Delft University of Technology, van der Maasweg 9, 2629 HZ Delft, Netherlands.
FEMS Microbiol Rev. 2022 Feb 9;46(1). doi: 10.1093/femsre/fuab048.
We are in the midst of a golden age of uncovering defense systems against bacteriophages. Apart from the fundamental interest in these defense systems, and revolutionary applications that have been derived from them (e.g. CRISPR-Cas9 and restriction endonucleases), it is unknown how defense systems contribute to resistance formation against bacteriophages in clinical settings. Bacteriophages are now being reconsidered as therapeutic agents against bacterial infections due the emergence of multidrug resistance. However, bacteriophage resistance through defense systems and other means could hinder the development of successful phage-based therapies. Here, we review the current state of the field of bacteriophage defense, highlight the relevance of bacteriophage defense for potential clinical use of bacteriophages as therapeutic agents and suggest new directions of research.
我们正处于揭示抗噬菌体防御系统的黄金时代。除了这些防御系统本身的基础研究兴趣,以及从中衍生出的革命性应用(如 CRISPR-Cas9 和限制内切酶)之外,人们还不知道防御系统在临床环境中对抗噬菌体的耐药性形成有何贡献。由于多药耐药性的出现,噬菌体现在正被重新考虑作为治疗细菌感染的药物。然而,通过防御系统和其他手段产生的噬菌体耐药性可能会阻碍成功的噬菌体疗法的发展。在这里,我们回顾了噬菌体防御领域的现状,强调了噬菌体防御对于噬菌体作为治疗剂在潜在临床应用中的相关性,并提出了新的研究方向。